Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7805259 | 1.00 | EGFR (0.60) | EGFRMEN1KMT2AERBB2PTP4A3 | |
| SCHEMBL8933994 | 0.91 | EGFR (0.61) | EGFRMEN1KMT2AERBB2PTP4A3 | |
| SCHEMBL8957270 | 0.91 | EGFR (0.61) | EGFRMEN1KMT2AERBB2PTP4A3 | |
| SCHEMBL9472266 | 0.78 | EGFR (0.67) | EGFRMEN1KMT2AIGF1RPOLB | |
| SCHEMBL9472275 | 0.78 | EGFR (0.67) | EGFRMEN1KMT2AIGF1RPOLB | |
| SCHEMBL9471772 | 0.76 | EGFR (0.66) | EGFRMEN1KMT2AERBB2ALDH1A1 | |
| SCHEMBL29429743 | 0.75 | EGFR (1.00) | EGFRMEN1KMT2AERBB2IGF1R | |
| SCHEMBL14040838 | 0.72 | EGFR (0.78) | EGFRMEN1KMT2AERBB2 | |
| SCHEMBL10338648 | 0.71 | EGFR (0.67) | EGFRMEN1KMT2AERBB2MAPT | |
| SCHEMBL10338647 | 0.71 | EGFR (0.67) | EGFRMEN1KMT2AERBB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | PANETTA JILL (US) | 2001-08-30 | — | — | US | disclosed |
| US-5981523-A | ADMINISTERING THIOMORPHOLINONE COMPOUND TO THE PATIENT SUFFERING FROM MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0779282-A1 | Thiomorpholinone compounds for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | TXNRD3, TXNRD2, CTH | EGFR 4634/4885MEN1 3945/4885KMT2A 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.